Deaths Prompt Warnings On Psoriasis Drug Raptiva

Law360, New York (February 19, 2009, 12:00 AM EST) -- Genentech Inc.'s psoriasis drug Raptiva came under attack Thursday on both sides of the Atlantic after reports that three patients using the drug died of a rare brain infection. Officials in the U.S. issued a public health advisory, while their counterparts in Europe recommended a halt to Raptiva sales.

The U.S. Food and Drug Administration said in a statement that it had confirmed that four people taking Raptiva contracted progressive multifocal leukoencephalopathy, a viral infection that damages the protective sheath surrounding nerves and usually leads to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.